Ajanta Pharma reported a 4% year-on-year increase in net profit for the first quarter of FY25, with earnings reaching Rs. 255 crore. The company’s consistent performance was driven by robust growth across its branded generics markets, especially in Asia and Africa. Revenue from operations grew modestly, supported by strategic focus on core therapeutic segments and efficient cost control. While domestic business remained stable, exports provided the key boost.